Lung cancer and the debrisoquine metabolic phenotype

Neil E. Caporaso, Margaret A. Tucker, Robert N. Hoover, Richard B. Hayes, Linda W. Pickle, Haleem J. Issaq, Gary M. Muschik, Laureen Green-gallo, Daina Buivys, Seena Aisner, James H. Resau, Benjamin F. Trump, David Tollerud, Aimsley Weston, Curtis C. Harris

Research output: Contribution to journalArticle

165 Citations (Scopus)

Abstract

In a case-control study, we tested the hypothesis that the genetically determined ability to metabolize debrisoquine is related to risk of lung cancer. Overall, individuals who were extensive metabolizers of debrisoquine were at significantly greater risk of lung cancer than those who were poor or intermediate metabolizers (odds ratio = 6.1; 95% confidence interval = 2.2-17.1). In this study, case patients had lung cancer, and control subjects had either chronic obstructive c pulmonary disease or cancers other than lung cancer. Results were adjusted for age, race, asbestos exposure, and smoking. Both black and white individuals who were extensive metab-olizers of debrisoquine were at significantly increased risk after similar adjustment (for blacks, odds ratio =4.5, 95% c confidence interval = 1.1-18.1; for whites, odds ratio =10.2, 95% confidence interval = 2.0-51.4). Significantly increased risk of lung cancer was also present for individuals who were extensive metabolizers when subjects with chronic obstruc- tive pulmonary disease or other cancers were considered separately. These data confirm that the ability to metabolize debrisoquine is a major determinant of susceptibility to lung cancer. Evaluation of the marker in other case-control I settings, further exploration of racial differences, and the prospective evaluation of this marker in subgroups at high risk of lung cancer are areas worthy of further study. [J Natl Cancer Inst 82: 1264-1272, 1990].

Original languageEnglish (US)
Pages (from-to)1264-1272
Number of pages9
JournalJournal of the National Cancer Institute
Volume82
Issue number15
DOIs
StatePublished - Aug 1 1990

Fingerprint

Debrisoquin
Lung Neoplasms
Phenotype
Aptitude
Odds Ratio
Confidence Intervals
Chronic Obstructive Pulmonary Disease
Social Adjustment
Asbestos
Case-Control Studies
Neoplasms
Smoking

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Caporaso, N. E., Tucker, M. A., Hoover, R. N., Hayes, R. B., Pickle, L. W., Issaq, H. J., ... Harris, C. C. (1990). Lung cancer and the debrisoquine metabolic phenotype. Journal of the National Cancer Institute, 82(15), 1264-1272. https://doi.org/10.1093/jnci/82.15.1264
Caporaso, Neil E. ; Tucker, Margaret A. ; Hoover, Robert N. ; Hayes, Richard B. ; Pickle, Linda W. ; Issaq, Haleem J. ; Muschik, Gary M. ; Green-gallo, Laureen ; Buivys, Daina ; Aisner, Seena ; Resau, James H. ; Trump, Benjamin F. ; Tollerud, David ; Weston, Aimsley ; Harris, Curtis C. / Lung cancer and the debrisoquine metabolic phenotype. In: Journal of the National Cancer Institute. 1990 ; Vol. 82, No. 15. pp. 1264-1272.
@article{cb85977faf45466a9d96cc49048ad5c0,
title = "Lung cancer and the debrisoquine metabolic phenotype",
abstract = "In a case-control study, we tested the hypothesis that the genetically determined ability to metabolize debrisoquine is related to risk of lung cancer. Overall, individuals who were extensive metabolizers of debrisoquine were at significantly greater risk of lung cancer than those who were poor or intermediate metabolizers (odds ratio = 6.1; 95{\%} confidence interval = 2.2-17.1). In this study, case patients had lung cancer, and control subjects had either chronic obstructive c pulmonary disease or cancers other than lung cancer. Results were adjusted for age, race, asbestos exposure, and smoking. Both black and white individuals who were extensive metab-olizers of debrisoquine were at significantly increased risk after similar adjustment (for blacks, odds ratio =4.5, 95{\%} c confidence interval = 1.1-18.1; for whites, odds ratio =10.2, 95{\%} confidence interval = 2.0-51.4). Significantly increased risk of lung cancer was also present for individuals who were extensive metabolizers when subjects with chronic obstruc- tive pulmonary disease or other cancers were considered separately. These data confirm that the ability to metabolize debrisoquine is a major determinant of susceptibility to lung cancer. Evaluation of the marker in other case-control I settings, further exploration of racial differences, and the prospective evaluation of this marker in subgroups at high risk of lung cancer are areas worthy of further study. [J Natl Cancer Inst 82: 1264-1272, 1990].",
author = "Caporaso, {Neil E.} and Tucker, {Margaret A.} and Hoover, {Robert N.} and Hayes, {Richard B.} and Pickle, {Linda W.} and Issaq, {Haleem J.} and Muschik, {Gary M.} and Laureen Green-gallo and Daina Buivys and Seena Aisner and Resau, {James H.} and Trump, {Benjamin F.} and David Tollerud and Aimsley Weston and Harris, {Curtis C.}",
year = "1990",
month = "8",
day = "1",
doi = "10.1093/jnci/82.15.1264",
language = "English (US)",
volume = "82",
pages = "1264--1272",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "15",

}

Caporaso, NE, Tucker, MA, Hoover, RN, Hayes, RB, Pickle, LW, Issaq, HJ, Muschik, GM, Green-gallo, L, Buivys, D, Aisner, S, Resau, JH, Trump, BF, Tollerud, D, Weston, A & Harris, CC 1990, 'Lung cancer and the debrisoquine metabolic phenotype', Journal of the National Cancer Institute, vol. 82, no. 15, pp. 1264-1272. https://doi.org/10.1093/jnci/82.15.1264

Lung cancer and the debrisoquine metabolic phenotype. / Caporaso, Neil E.; Tucker, Margaret A.; Hoover, Robert N.; Hayes, Richard B.; Pickle, Linda W.; Issaq, Haleem J.; Muschik, Gary M.; Green-gallo, Laureen; Buivys, Daina; Aisner, Seena; Resau, James H.; Trump, Benjamin F.; Tollerud, David; Weston, Aimsley; Harris, Curtis C.

In: Journal of the National Cancer Institute, Vol. 82, No. 15, 01.08.1990, p. 1264-1272.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lung cancer and the debrisoquine metabolic phenotype

AU - Caporaso, Neil E.

AU - Tucker, Margaret A.

AU - Hoover, Robert N.

AU - Hayes, Richard B.

AU - Pickle, Linda W.

AU - Issaq, Haleem J.

AU - Muschik, Gary M.

AU - Green-gallo, Laureen

AU - Buivys, Daina

AU - Aisner, Seena

AU - Resau, James H.

AU - Trump, Benjamin F.

AU - Tollerud, David

AU - Weston, Aimsley

AU - Harris, Curtis C.

PY - 1990/8/1

Y1 - 1990/8/1

N2 - In a case-control study, we tested the hypothesis that the genetically determined ability to metabolize debrisoquine is related to risk of lung cancer. Overall, individuals who were extensive metabolizers of debrisoquine were at significantly greater risk of lung cancer than those who were poor or intermediate metabolizers (odds ratio = 6.1; 95% confidence interval = 2.2-17.1). In this study, case patients had lung cancer, and control subjects had either chronic obstructive c pulmonary disease or cancers other than lung cancer. Results were adjusted for age, race, asbestos exposure, and smoking. Both black and white individuals who were extensive metab-olizers of debrisoquine were at significantly increased risk after similar adjustment (for blacks, odds ratio =4.5, 95% c confidence interval = 1.1-18.1; for whites, odds ratio =10.2, 95% confidence interval = 2.0-51.4). Significantly increased risk of lung cancer was also present for individuals who were extensive metabolizers when subjects with chronic obstruc- tive pulmonary disease or other cancers were considered separately. These data confirm that the ability to metabolize debrisoquine is a major determinant of susceptibility to lung cancer. Evaluation of the marker in other case-control I settings, further exploration of racial differences, and the prospective evaluation of this marker in subgroups at high risk of lung cancer are areas worthy of further study. [J Natl Cancer Inst 82: 1264-1272, 1990].

AB - In a case-control study, we tested the hypothesis that the genetically determined ability to metabolize debrisoquine is related to risk of lung cancer. Overall, individuals who were extensive metabolizers of debrisoquine were at significantly greater risk of lung cancer than those who were poor or intermediate metabolizers (odds ratio = 6.1; 95% confidence interval = 2.2-17.1). In this study, case patients had lung cancer, and control subjects had either chronic obstructive c pulmonary disease or cancers other than lung cancer. Results were adjusted for age, race, asbestos exposure, and smoking. Both black and white individuals who were extensive metab-olizers of debrisoquine were at significantly increased risk after similar adjustment (for blacks, odds ratio =4.5, 95% c confidence interval = 1.1-18.1; for whites, odds ratio =10.2, 95% confidence interval = 2.0-51.4). Significantly increased risk of lung cancer was also present for individuals who were extensive metabolizers when subjects with chronic obstruc- tive pulmonary disease or other cancers were considered separately. These data confirm that the ability to metabolize debrisoquine is a major determinant of susceptibility to lung cancer. Evaluation of the marker in other case-control I settings, further exploration of racial differences, and the prospective evaluation of this marker in subgroups at high risk of lung cancer are areas worthy of further study. [J Natl Cancer Inst 82: 1264-1272, 1990].

UR - http://www.scopus.com/inward/record.url?scp=0025291440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025291440&partnerID=8YFLogxK

U2 - 10.1093/jnci/82.15.1264

DO - 10.1093/jnci/82.15.1264

M3 - Article

C2 - 2374176

AN - SCOPUS:0025291440

VL - 82

SP - 1264

EP - 1272

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 15

ER -

Caporaso NE, Tucker MA, Hoover RN, Hayes RB, Pickle LW, Issaq HJ et al. Lung cancer and the debrisoquine metabolic phenotype. Journal of the National Cancer Institute. 1990 Aug 1;82(15):1264-1272. https://doi.org/10.1093/jnci/82.15.1264